Remdesivir’s controversial cost, early vaccine data, and AI at the end of life

Remdesivir’s controversial cost, early vaccine data, and AI at the end of life

hat’s a fair price for remdesivir? How do we know whether vaccines work? And does AI have a place in end-of-life care? We discuss all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we dig into the long-awaited price for Gilead Sciences’ Covid-19 treatment and break down the disparate reactions from lawmakers, activists, and Wall Street analysts.

By Miki